SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.
SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.
SCYNEXIS, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 25, 2026. Proposals include electing six directors, ratifying Deloitte & Touche LLP, an advisory say-on-pay vote and say-on-pay frequency, and governance items.
The company seeks approval to amend its 2024 Equity Incentive Plan to increase the share reserve by 9,600,000 shares and to amend its certificate of incorporation to raise authorized common stock to either 60,000,000 or 300,000,000 shares, depending on a separate reverse stock split outcome. SCYNEXIS had 79,442,633 shares of common stock outstanding and entitled to vote as of April 27, 2026.
SCYNEXIS, Inc. Schedule 13G shows CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. report beneficial ownership of 3,008,874 shares of SCYNEXIS common stock, representing 6.7% of the class. The reported shares consist of warrants exercisable subject to 4.99% and 9.99% ownership caps. Shares outstanding were 41,924,941 as of August 8, 2025.
SCYNEXIS, Inc. is calling a virtual special stockholder meeting on May 19, 2026 to seek approval for a reverse stock split of its common stock at a ratio between 1‑for‑5 and 1‑for‑10, along with a proportional reduction in authorized shares. The board states this flexibility is intended to help the company regain compliance with The Nasdaq Capital Market’s minimum bid price requirement before June 15, 2026 and avoid potential delisting proceedings. As of April 20, 2026, the company had 79,442,633 common shares outstanding and 150,000,000 authorized, which would all be reduced proportionately if the split is implemented.
SCYNEXIS, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held on June 25, 2026. The Board asks shareholders to elect six directors, ratify Deloitte & Touche LLP as auditor, approve advisory votes on executive compensation and frequency, approve an increase to the 2024 Equity Incentive Plan share reserve, and approve an amendment to increase authorized common stock to either 60,000,000 (with a reverse split condition) or 300,000,000.
The record date was April 27, 2026. The Board recommends voting FOR all proposals, including a proposed 9,600,000-share increase to the 2024 Plan reserve and the plan amendment that results in a 21,410,683 share maximum under the amended plan. Proxy materials and voting instructions are available online.
SCYNEXIS, Inc. reported that board member Steven C. Gilman plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His term will end at that meeting, when his current directorship expires.
Until the 2026 annual meeting, Dr. Gilman will continue to serve as Chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. The company stated that his decision was not due to any disagreement regarding its operations, policies, practices, strategy, management, or Board.
SCYNEXIS, Inc. is asking shareholders at a virtual Special Meeting on May 19, 2026 to approve an amendment to its certificate of incorporation to permit a reverse stock split of its common stock at a ratio the Board may choose in the range 1-for-5 through 1-for-10. The Board would have discretion whether and when to implement the approved split and to abandon it despite shareholder approval.
The company states the board seeks flexibility to regain or maintain Nasdaq listing compliance and to reduce outstanding share counts; authorized common shares and outstanding shares would be reduced proportionately if the Board effects the split. The record date for voting is April 20, 2026, and proxy materials are available at www.proxyvote.com.
SCYNEXIS INC reports a passive ownership filing showing 7,608,695 shares (9.6% of the class) held by Squadron Master Fund LP and related reporting persons as of 03/31/2026. The statement lists shared voting and dispositive power for the reported holders and cites 79,442,633 shares outstanding as the basis for the percentage calculation.
Great Point Partners, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl report joint beneficial ownership of 7,978,713 shares of SCYNEXIS common stock, representing 9.99% of the class as of 03/31/2026. The filing bases the percentage on a total of 79,866,999 shares outstanding, which includes 424,366 shares issuable upon exercise of warrants held by the reporting persons limited by a Beneficial Ownership Cap. The reporting persons hold 7,554,347 shares outright and hold warrants comprising 8,750,000 pre-funded warrants and 16,304,347 common warrants, subject to exercise limits. The statement also discloses related record holdings: 4,985,869 shares held by Biomedical Value Fund, L.P. and 2,568,478 shares held by Biomedical Offshore Value Fund, Ltd.
SCYNEXIS INC Chief Executive Officer David Angulo Gonzalez purchased additional equity through a private placement. On March 30, 2026, he agreed to buy 108,695 shares of common stock and accompanying warrants to purchase up to 108,695 shares, which closed on April 1, 2026, at a combined purchase price of $0.92 per share and warrant unit. The new Common Warrants will become exercisable once stockholders approve an increase in authorized common shares and will expire on the earlier of five years from issuance or 30 days after SCYNEXIS releases Week 48 topline data from its Phase 2 proof-of-concept clinical study of SCY-770 in autosomal dominant polycystic kidney disease. Following these transactions, he directly owns 1,357,126 shares of common stock, including 4,000 acquired under the 2014 Employee Stock Purchase Plan.